OncoSec Medical Inc Share Price OTC Bulletin Board
Equities
ONCS
US68234L1089
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
2023 | Motion for Asset Sale Approved for OncoSec Medical Incorporated | CI |
2023 | Motion for Asset Sale Filed by OncoSec Medical Incorporated | CI |
Sales 2021 | - | Sales 2022 | - | Capitalization | 28.35M 2.27B |
---|---|---|---|---|---|
Net income 2021 | -45M -3.6B | Net income 2022 | -34M -2.72B | EV / Sales 2021 | - |
Net cash position 2021 | 33.63M 2.69B | Net cash position 2022 | 1.12M 89.89M | EV / Sales 2022 | - |
P/E ratio 2021 |
-1.59
x | P/E ratio 2022 |
-0.83
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 84.57% |
Managers | Title | Age | Since |
---|---|---|---|
David Canton
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/13 |
Sandra Aung
PRN | Corporate Officer/Principal | - | 11/10/20 |
Bridget O'Keeffe
PRN | Corporate Officer/Principal | - | 17/02/21 |
1st Jan change | Capi. | |
---|---|---|
+0.67% | 42.4B | |
+46.85% | 40.04B | |
-6.20% | 28.31B | |
+6.55% | 24.94B | |
-21.66% | 18.96B | |
+29.96% | 12.3B | |
-1.57% | 11.95B | |
+16.03% | 11.32B | |
-4.80% | 11.55B |
- Stock Market
- Equities
- ONCSQ Stock
- ONCS Stock